RPI.4610 in Treating Patients With Metastatic Kidney Cancer

NCT ID: NCT00021021

Last Updated: 2013-03-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-09-30
• Study Completion Date: 2004-02-29

Brief Summary

RATIONALE: RPI.4610 may stop the growth of metastatic kidney cancer by stopping blood flow to the tumor.

PURPOSE: Phase II trial to study the effectiveness of RPI.4610 in treating patients who have metastatic kidney cancer.

Detailed Description

OBJECTIVES: I. Determine the response rate of patients with metastatic renal cell cancer treated with RPI.4610. II. Determine the percentage of these patients with stable disease at 16 weeks after starting treatment with this drug. III. Assess the safety and tolerability of this drug in these patients.

OUTLINE: This is a multicenter study. Patients receive RPI.4610 subcutaneously daily. Treatment continues for 16 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue treatment after 16 weeks. Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Conditions

Kidney Cancer

Study Design

• Primary Study Purpose: TREATMENT

Interventions

anti-FLT-1 ribozyme

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin greater than 9.5 g/dL No history of bleeding disorder Hepatic: AST or ALT no greater than 3 times upper limit of normal (ULN) Bilirubin no greater than 1.5 times ULN (unless history of Gilbert's syndrome) Alkaline phosphatase no greater than 2.5 times ULN PT no greater than 15 sec INR no greater than 1.5 No history of cirrhosis Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No New York Heart Association class III or IV heart disease No uncontrolled hypertension, defined as newly diagnosed but untreated or treated but with diastolic blood pressure at least 95 mmHg or systolic blood pressure at least 160 mmHg Other: HIV negative No systemic infection requiring antibiotics within the past 28 days No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No alcohol or drug abuse within the past 2 years No other medical or psychiatric condition that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 1 month after study

PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 4 weeks since prior IL-2 At least 6 months since prior biotherapy for metastases (e.g., vaccines, matrix metalloproteinase inhibitors, or antibody therapy) No prior antiangiogenic agent, including thalidomide, or experimental antiangiogenic agents No concurrent immunotherapy No other concurrent biotherapy Chemotherapy: No prior chemotherapy for metastatic renal cell cancer No concurrent chemotherapy Endocrine therapy: No concurrent estrogens or other hormonal therapy including androgens Concurrent replacement doses of steroids allowed provided stable for the past 28 doses Radiotherapy: At least 8 weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics At least 4 weeks since prior major surgery Other: At least 4 weeks since prior investigational drugs No other concurrent investigational drugs No concurrent immunosuppressive medications No concurrent warfarin, heparin, low molecular weight heparin, or other anticoagulant agents

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ribozyome

INDUSTRY

Sponsor Role: lead

Principal Investigators

Robert A. Figlin, MD, FACP

Role: STUDY_CHAIR

Jonsson Comprehensive Cancer Center

Locations

Jonsson Comprehensive Cancer Center, UCLA

Los Angeles, California, United States

Countries

United States

Other Identifiers

UCLA-001201501

Identifier Type: -

Identifier Source: secondary_id

RPI-0004

Identifier Type: -

Identifier Source: secondary_id

NCI-G01-1975

Identifier Type: -

Identifier Source: secondary_id

CDR0000068739

Identifier Type: -

Identifier Source: org_study_id